Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 109M | 69M | 53M | 40M | 25M |
| Gross Profit | 76M | 55M | 43M | 33M | 19M |
| Operating Income | 12M | 10M | 7M | 5M | 324K |
| EBITDA | 23M | 12M | 10M | 7M | 3M |
| Net Income | 6M | 3M | 5M | 1M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.04
+0.00% today
1Y Change
-37.04%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vitalhub Corp. (VHIBF) is a Healthcare stock with a market cap of $510.00M and listed on OTC. The stock last traded around $5.04 and down 37.0% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +58.7%, EPS growth of +63.9%, a dividend yield of 0.0%. What stands out right now is revenue +58.7%, EPS +63.9%, free cash flow -44.6% with operating margin 11.2% and ROIC 4.2%. Valuation already assumes a fairly strong business story at P/E 80.3 and price/sales 4.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VHIBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VHIBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VHIBF Max Drawdown
-52.68%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VHIBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$24.7M
-38.3% YoY
FY Net Income
-$1.9M
-260.3% YoY
Free Cash Flow
-$309.6K
-105.3% YoY
Revenue Growth
+58.7%
EPS Growth
+63.9%
Gross Margin
77.2%
Net Margin
5.6%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 109M | 69M | 53M | 40M | 25M |
| Gross Profit | 76M | 55M | 43M | 33M | 19M |
| Operating Income | 12M | 10M | 7M | 5M | 324K |
| EBITDA | 23M | 12M | 10M | 7M | 3M |
| Net Income | 6M | 3M | 5M | 1M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 58M | 57M | 33M | 17M | 16M |
| Total Assets | 352M | 207M | 119M | 106M | 73M |
| Total Liabilities | 87M | 62M | 37M | 31M | 18M |
| Shareholder Equity | 266M | 145M | 82M | 75M | 55M |
| Total Debt | 3M | 609K | 541K | 882K | 793K |
| Net Debt | -55M | -56M | -33M | -17M | -16M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
50K
-100.8% YoY
Capital Expenditures
260K
+12.0% YoY
Free Cash Flow
310K
-105.3% YoY
Key ratios
Gross Margin
77.2%
Operating Margin
11.2%
Net Margin
5.6%
ROE
2.7%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.